Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Merck (MRK) to $82 from $89 and keeps a Market Perform rating on the ...

Robert F. Kennedy Jr. and I rarely see eye to eye, but I’ll grudgingly admit he’s not entirely wrong about food dyes, though ...

As U.S. President Donald Trump's trade war with China devolves into a "he said, Xi said" back-and-forth over whether the ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target ...

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.